News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunitor USA Inc.'s V5 Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week



11/1/2010 11:47:55 AM

VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis. V5 is an orally delivered once-daily tablet that in combination with standard TB drugs had so far produced clearance of Mycobacterium tuberculosis in sputum smear of about 95% of treated TB patients within one month.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES